

March 30, 2022

**BSE Limited**  
P. J. Towers,  
Dalai Street,  
Mumbai- 400 001  
Scrip Code-540025

**National Stock Exchange of India Ltd.**  
Exchange Plaza, Plot No. C/1,  
G Block Bandra-Kurla Complex,  
Bandra (E) Mumbai- 400 051  
Trading Symbol-ADVENZYMES

**Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR")**

**Ref: ISIN: INE837H01020**

This is to inform you that the Board of Directors of the Company ("Board") at their meeting held today i.e. on March 30, 2022, has appointed Mr. Nitin Jagannath Deshmukh (DIN: 00060743) as an Additional Director (Independent), with effect from July 01, 2022, to hold office up to the date of ensuing Annual General Meeting of the Company ("AGM") or the date up to which AGM shall be held, whichever is earlier. Subject to approval of the Members at the ensuing AGM of the Company, Mr. Nitin Deshmukh shall hold office as an Independent Director for a period of 5 (five) years effective from July 01, 2022.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 are annexed herewith as Annexure-I.

Further, we would like to inform that consequent to attaining retirement age (as per the Company's policy), the Board has extended the tenure of Mr. Beni Prasad Rauka as Chief Financial Officer (Key Managerial Personnel) of the Company for a period of ten (10) years from April 01, 2022 till March 31, 2032.

This is for your information and for public at large.

Thanking you,  
Yours faithfully,

**For Advanced Enzyme Technologies Limited**



**Sanjay Basantani**  
**Company Secretary & Head -Legal**

Encl: As above



**Annexure – I**

**Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No.CIR/CFD/CMD/4/2015 dated September 09, 2015 – Appointment of Mr. Nitin Jagannath Deshmukh as an Additional Director (Independent):**

<b>Reason for change viz. appointment, resignation, removal, death or otherwise;</b>	Appointment
<b>Date of appointment &amp; term of appointment</b>	July 01, 2022  Subject to approval of the Members at the ensuing AGM of the Company, Mr. Nitin Deshmukh shall hold office as an Independent Director for a period of 5 (five) years effective from July 01, 2022.
<b>Brief profile</b>	Mr. Nitin Deshmukh, aged 59 years, currently serves as an Advisor at Kotak Investment Advisors Limited and holds several Board and Advisory Board positions. Mr. Deshmukh has previously held investment roles at Kotak Investment Advisors Limited, ICICI Venture Funds Management Company Limited, Dresdner Kleinwort Benson Advisory Services (India) Private Limited and on the operations side with Cipla Limited. He holds a postgraduate degree in Pharmacy from the University of Mumbai and a postgraduate degree in Management from University of Mumbai. He has also completed a Post Graduate Program in Pharmaceutical Technology from University of Ghent, Belgium. He is a Distinguished Alumnus of the Institute of Chemical Technology (earlier known as UDCT).
<b>Disclosure of relationships between directors</b>	Mr. Nitin Deshmukh is not Related to any Directors of the Company.
<b>Information as per circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/24 dated June 20, 2018 issued by BSE and NSE respectively.</b>	Mr. Nitin Deshmukh is not debarred from holding the office of Director by virtue of any SEBI order or any such other authority.



\*\*\*\*\*